PE20020593A1 - Activadores de glucocinasa del tipo isoindolin-2-ona - Google Patents

Activadores de glucocinasa del tipo isoindolin-2-ona

Info

Publication number
PE20020593A1
PE20020593A1 PE2001001234A PE2001001234A PE20020593A1 PE 20020593 A1 PE20020593 A1 PE 20020593A1 PE 2001001234 A PE2001001234 A PE 2001001234A PE 2001001234 A PE2001001234 A PE 2001001234A PE 20020593 A1 PE20020593 A1 PE 20020593A1
Authority
PE
Peru
Prior art keywords
isoindolin
ona
type
propionamide
cyclohexil
Prior art date
Application number
PE2001001234A
Other languages
English (en)
Spanish (es)
Inventor
Kevin Richard Guertin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020593A1 publication Critical patent/PE20020593A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
PE2001001234A 2000-12-13 2001-12-11 Activadores de glucocinasa del tipo isoindolin-2-ona PE20020593A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25527300P 2000-12-13 2000-12-13
US31871501P 2001-09-13 2001-09-13

Publications (1)

Publication Number Publication Date
PE20020593A1 true PE20020593A1 (es) 2002-07-06

Family

ID=26944583

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001234A PE20020593A1 (es) 2000-12-13 2001-12-11 Activadores de glucocinasa del tipo isoindolin-2-ona

Country Status (35)

Country Link
US (1) US6482951B2 (https=)
EP (1) EP1349856B1 (https=)
JP (1) JP4021766B2 (https=)
KR (1) KR100520651B1 (https=)
CN (1) CN1247574C (https=)
AT (1) ATE297922T1 (https=)
AU (2) AU2002238415B2 (https=)
BG (1) BG107903A (https=)
BR (1) BR0116169A (https=)
CA (1) CA2430579C (https=)
CY (1) CY1105587T1 (https=)
CZ (1) CZ20031882A3 (https=)
DE (1) DE60111570T2 (https=)
DK (1) DK1349856T3 (https=)
EG (1) EG24358A (https=)
ES (1) ES2243578T3 (https=)
HR (1) HRP20030450B1 (https=)
HU (1) HUP0400587A3 (https=)
IL (2) IL156264A0 (https=)
MA (1) MA26973A1 (https=)
MX (1) MXPA03005170A (https=)
MY (1) MY136741A (https=)
NO (1) NO325810B1 (https=)
NZ (1) NZ526236A (https=)
PA (1) PA8534601A1 (https=)
PE (1) PE20020593A1 (https=)
PL (1) PL366006A1 (https=)
PT (1) PT1349856E (https=)
RS (1) RS50933B (https=)
RU (1) RU2249590C2 (https=)
SI (1) SI1349856T1 (https=)
SK (1) SK8732003A3 (https=)
TW (1) TWI294876B (https=)
UY (1) UY27069A1 (https=)
WO (1) WO2002048106A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
PL375149A1 (en) 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7262196B2 (en) * 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US7781451B2 (en) * 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
BRPI0509573A (pt) 2004-04-02 2007-09-25 Novartis Ag derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
KR101346902B1 (ko) 2005-07-09 2014-01-02 아스트라제네카 아베 당뇨병 치료에 있어 glk 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체
WO2007026761A1 (ja) * 2005-08-31 2007-03-08 Astellas Pharma Inc. チアゾール誘導体
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
CN101316836A (zh) 2005-11-01 2008-12-03 詹森药业有限公司 作为葡萄糖激酶变构调节剂的取代的二氢异吲哚酮类
EP1951706A1 (en) 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
EP1960386A2 (en) * 2005-11-01 2008-08-27 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
CA2627813A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
WO2007051845A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
EP2001875A2 (en) * 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
JP5248477B2 (ja) * 2007-03-07 2013-07-31 杏林製薬株式会社 グルコキナーゼ活性化物質
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
TW200934772A (en) * 2008-01-15 2009-08-16 Lilly Co Eli Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
WO2009092432A1 (en) * 2008-01-24 2009-07-30 Merck Patent Gmbh Beta-amino acid derivatives for treatment of diabetes
KR101608259B1 (ko) * 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체
KR20110018366A (ko) * 2008-05-16 2011-02-23 다케다 샌디에고, 인코포레이티드 글루코키나아제 활성제
AU2009290474A1 (en) * 2008-09-11 2010-03-18 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8178689B2 (en) * 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
SI3004076T1 (sl) * 2013-05-27 2020-02-28 F. Hoffmann-La Roche Ag Novi spojini 3,4-dihidro-2H-izokinolin-1-on in 2,3-dihidro-izoindol-1-on
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN116283717B (zh) * 2023-01-06 2025-04-08 暨南大学 一种藁本内酯衍生物及其制备方法和应用
WO2024229228A2 (en) * 2023-05-02 2024-11-07 The Rockefeller University 1-oxoisoindolin-2-yl amide activators of vcp and derivatives thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687147A1 (fr) * 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
PL350669A1 (en) 1999-03-29 2003-01-27 Hoffmann La Roche Glucokinase activators
AU5227001A (en) 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators
DK1282611T3 (da) 2000-05-08 2005-02-14 Hoffmann La Roche Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer

Also Published As

Publication number Publication date
KR20030064817A (ko) 2003-08-02
EG24358A (en) 2009-03-04
CA2430579C (en) 2010-01-26
IL156264A (en) 2010-11-30
US20020082260A1 (en) 2002-06-27
UY27069A1 (es) 2002-07-31
EP1349856B1 (en) 2005-06-15
CA2430579A1 (en) 2002-06-20
NZ526236A (en) 2004-12-24
MXPA03005170A (es) 2003-09-22
NO20032674D0 (no) 2003-06-12
HUP0400587A3 (en) 2011-03-28
DE60111570T2 (de) 2006-05-11
PT1349856E (pt) 2005-09-30
HUP0400587A2 (hu) 2004-06-28
PA8534601A1 (es) 2002-08-26
KR100520651B1 (ko) 2005-10-11
WO2002048106A2 (en) 2002-06-20
BG107903A (bg) 2004-02-27
CN1481382A (zh) 2004-03-10
BR0116169A (pt) 2003-12-23
CY1105587T1 (el) 2010-07-28
WO2002048106A3 (en) 2002-11-28
HK1063314A1 (en) 2004-12-24
NO20032674L (no) 2003-06-12
RS50933B (sr) 2010-08-31
IL156264A0 (en) 2004-01-04
SI1349856T1 (en) 2005-10-31
MA26973A1 (fr) 2004-12-20
MY136741A (en) 2008-11-28
US6482951B2 (en) 2002-11-19
ATE297922T1 (de) 2005-07-15
NO325810B1 (no) 2008-07-21
AU2002238415B2 (en) 2007-01-04
DK1349856T3 (da) 2005-10-17
CN1247574C (zh) 2006-03-29
JP4021766B2 (ja) 2007-12-12
CZ20031882A3 (cs) 2003-12-17
PL366006A1 (en) 2005-01-24
RU2249590C2 (ru) 2005-04-10
JP2004521095A (ja) 2004-07-15
HRP20030450A2 (en) 2005-04-30
ES2243578T3 (es) 2005-12-01
YU47703A (sh) 2006-05-25
SK8732003A3 (en) 2004-04-06
HRP20030450B1 (en) 2006-02-28
DE60111570D1 (de) 2005-07-21
AU3841502A (en) 2002-06-24
TWI294876B (en) 2008-03-21
EP1349856A2 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
PE20020593A1 (es) Activadores de glucocinasa del tipo isoindolin-2-ona
PA8503301A1 (es) Compuestos para el tratamiento de la isquemia
AR027406A1 (es) Moduladores de receptores canabinoides, sus procesos de preparacion y uso de los moduladores de receptores canabinoides para el tratamiento de enfermedadesrespiratorias y no respiratorias.
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
ECSP014055A (es) Activadores de glucoquinasa que contienen hidantoina
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
AR033306A1 (es) Compuestos
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
ATE361289T1 (de) Piperazinsubstituierte arylbenzodiazepine
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
AR020851A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos
PE20030713A1 (es) Derivados benzotiazol de nicotina o isonicotina
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
GB0517191D0 (en) Compounds
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
PE106099A1 (es) Uso de derivados hidroxicumaranonas sustituidos como agentes antitumorales y antimetastasicos
AR012878A1 (es) Un compuesto derivado de 5'-desoxicitidina, su uso, un proceso para fabricarlo, composiciones farmaceuticas que lo comprende, y un kit que comprende dicha composicion.
EA200600694A1 (ru) Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
ATE453610T1 (de) Antimikrobiell wirksame 4-methyl-4-aryl-2- pentanole, deren herstellung und verwendung
AR028776A1 (es) Derivados de la pirimidina y su uso para la profilaxis y la terapia de isquemia cerebral
AR028475A1 (es) Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
PE20061318A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed